| 7.51 0.4 (5.63%) | 07-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.87 |
1-year : | 10.36 |
| Resists | First : | 7.59 |
Second : | 8.87 |
| Pivot price | 6.96 |
|||
| Supports | First : | 6.18 |
Second : | 5.3 |
| MAs | MA(5) : | 7.05 |
MA(20) : | 6.84 |
| MA(100) : | 6.04 |
MA(250) : | 8.38  |
|
| MACD | MACD : | 0.3 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 69.5 |
D(3) : | 60.8 |
| RSI | RSI(14): 67.3 |
|||
| 52-week | High : | 13.88 | Low : | 4.44 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CERT ] has closed above the upper band by 6.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 35.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.61 - 7.64 | 7.64 - 7.67 |
| Low: | 7.06 - 7.09 | 7.09 - 7.12 |
| Close: | 7.45 - 7.51 | 7.51 - 7.56 |
Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and preclinical research to clinical trials, regulatory submissions, and market entry, the company's core mission is to accelerate the delivery of new medicines to patients by transforming these processes with its innovative biosimulation software and expertise. Its extensive portfolio of technology-enabled services includes mechanistic and empirical biosimulation, strategic guidance for drug development and regulatory affairs, clinical pharmacology, model-based meta-analysis, specialized regulatory writing and medical communications, regulatory operations support, and market access consultation. Furthermore, Certara offers a robust suite of software platforms covering mechanistic and empirical PK/PD biosimulation, data standardization and compliance, scientific informatics, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions, and market access communication. The company's clientele primarily comprises biopharmaceutical firms, academic institutions, and governmental organizations. Established in 2008 and headquartered in Princeton, New Jersey, Certara maintains a significant global presence, with operations spanning numerous countries including the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China.
Sat, 25 Jul 2026
Certara, Inc. (CERT) Q1 2024 Earnings Report - Results, Call & Slides - TipRanks
Fri, 24 Jul 2026
Certara, Inc. (CERT) Q1 2025 Earnings Report - Results, Call & Slides - TipRanks
Wed, 22 Jul 2026
How Certara’s NVIDIA AI Partnership Could Reshape CERT’s Long-Term Drug Development Narrative - webull.com
Wed, 15 Jul 2026
Certara sets Aug. 4 call to discuss second-quarter results - Stock Titan
Tue, 14 Jul 2026
Dimensional Fund Advisors details Certara Inc (CERT) 3.9% ownership position - Stock Titan
Wed, 17 Jun 2026
Is It Time To Consider Buying Certara, Inc. (NASDAQ:CERT)? - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 156 (M) |
| Shares Float | 107 (M) |
| Held by Insiders | 2.5 (%) |
| Held by Institutions | 111.8 (%) |
| Shares Short | 29,380 (K) |
| Shares Short P.Month | 28,750 (K) |
| EPS | -0.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.63 |
| Profit Margin | -3.6 % |
| Operating Margin | 3.7 % |
| Return on Assets (ttm) | 0.7 % |
| Return on Equity (ttm) | -1.5 % |
| Qtrly Rev. Growth | 0.8 % |
| Gross Profit (p.s.) | 1.66 |
| Sales Per Share | 2.69 |
| EBITDA (p.s.) | 0.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 91 (M) |
| Levered Free Cash Flow | 117 (M) |
| PE Ratio | -75.1 |
| PEG Ratio | 0 |
| Price to Book value | 1.13 |
| Price to Sales | 2.78 |
| Price to Cash Flow | 12.88 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|